sumitomo dainippon pharma co
(4506:Tokyo Stock Exchange)
Chiang J. Li M.D., FACP.
Head of Global Oncology, Executive Officer, Chief Executive Officer of Boston Biomedical, Inc, President of Boston Biomedical, Inc and Chief Medical Officer of Boston Biomedical, Inc, Sumitomo Dainippon Pharma Co., Ltd.
|Age||Total Calculated Compensation||This person is connected to 24 board members in 2 different organizations across 6 different industries.|
See Board Relationships
Dr. Chiang J. Li, M.D., FACP. serves as the President, Chief Executive Officer and Chief Medical Officer at Boston Biomedical, Inc. (BBI). Dr. Li serves as an Executive Officer and Head of Global Oncology of Sumitomo Dainippon Pharma Co., Ltd. He is the Founder of Cequent Pharmaceuticals, Inc. He serves as Head of Global Oncology at the DSP Group. Dr. Li served as the Chief Scientific Officer at Boston Biomedical, Inc. which he founded it in November 2006. He Founded ...
6-8 Doshomachi 2-chomePhone: 81 6 6203 5321
Osaka, -- 541-0045
Fax: 81 6 6202 6028
Board Members Memberships*
Founder, Chairman of the Scientific Advisory Board and Director
Founder, Chief Executive Officer, President and Chief Medical Officer
Former Scientific Advisor and Director
Harvard Medical School
Harvard-MIT Division of Health Sciences and Technology
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Jeffrey J. Clarke||Chief Executive Officer and Director|
Eastman Kodak Co.
|William S. Marth||Chief Executive Officer, President and Director|
Albany Molecular Research Inc.
|Shigetaka Komori||Chairman, Chief Executive Officer, Chairman of Compliance Committee and Chairman of Risk Management Committee|
FUJIFILM Holdings Corporation
|Dayanand Thandalam Sriram||Managing Director and Director|
GlaxoSmithKline Consumer Nigeria Plc
|Douglas L. Drysdale||Chairman, Chief Executive Officer and President|
Pernix Therapeutics Holdings, Inc.
|$814.6K||Compensation as of Fiscal Year 2014.|